Koss Olinger Consulting LLC Has $2.55 Million Stake in GSK plc (NYSE:GSK)

Koss Olinger Consulting LLC reduced its holdings in GSK plc (NYSE:GSK) by 0.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 62,386 shares of the pharmaceutical company’s stock after selling 495 shares during the quarter. Koss Olinger Consulting LLC’s holdings in GSK were worth $2,550,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. JTC Employer Solutions Trustee Ltd lifted its position in shares of GSK by 71.3% during the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock worth $909,063,000 after purchasing an additional 8,800,822 shares in the last quarter. Primecap Management Co. CA lifted its holdings in GSK by 13.9% during the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock worth $558,689,000 after buying an additional 1,773,020 shares in the last quarter. Mondrian Investment Partners LTD boosted its position in GSK by 37.8% in the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock valued at $236,250,000 after buying an additional 1,512,442 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of GSK by 180.0% in the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock valued at $95,129,000 after buying an additional 1,426,935 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of GSK during the second quarter worth $52,487,000. 15.74% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 10.00% of the stock is owned by corporate insiders.

GSK Stock Performance

Shares of GSK stock opened at $38.55 on Monday. The company has a market capitalization of $79.89 billion, a P/E ratio of 13.97, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The company’s 50 day moving average price is $41.44 and its two-hundred day moving average price is $41.25.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. On average, analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were given a dividend of $0.3843 per share. The ex-dividend date was Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a yield of 3.99%. GSK’s dividend payout ratio is 55.80%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on GSK shares. Jefferies Financial Group raised their price target on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.